Lars Ekman
InvestorExecutive Partner, Private Equity at Sofinnova Ventures · Board director at Aeovian Pharmaceuticals · Board director at Sophiris BIO
San Diego, California
Writes $100K – $5M checks · typically $1.5M
About
Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.
Contact· self-published, not guessed
Invests in
Biotech
Board director at Aeovian Pharmaceuticals
Intro paths
In turn, Lars can intro founders to Aeovian Pharmaceuticals's investors below.
Board director at Sophiris BIO
Intro paths
In turn, Lars can intro founders to Sophiris BIO's investors below.
Sophiris BIO's investors · 1
Experience
- Sofinnova VenturesExcecutive Partnercurrent2007 — presentLa Jolla - San Diego, Menlo Park, CA
- Elan PharmaceuticalsEVP, President of Research & Development2001 — 2007San Diego, San Francisco, New York, Dublin
- Schwarz PharmaPresident R&D1996 — 2001Greater Dusseldorf Area
- Pharmacia GmbHEVP, Research and Development1989 — 1996Erlangen, Bavaria, Germany
- Pharmacia ABVice President of Research and Development1983 — 1989Greater Stockholm Metropolitan Area
Skills & more
+8 more
CommercializationMedical DevicesClinical DevelopmentCorporate DevelopmentDrug DiscoveryClinical TrialsOncologyRegulatory Affairs- Board Certified Surgeon — The Swedish Medical Association
From Lars's professional profile.
Deals · 1
Aeovian PharmaceuticalsBoard seat
via Sofinnova Ventures · filed Dec 2025 · $55M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
AeovianAfyx TherapeuticsAmarin (AMRN)Prothena (PRTA)Sophiris (SPHS)Spark (ONCE)
Sources: the firm's website · SEC Form D filings.
Colleagues at Sofinnova Ventures
Frequently asked questions
- Who is Lars Ekman?
- Lars Ekman is a global R&D executive and drug developer with more than 30 years of experience across executive, scientific, and clinical roles, and he brings his life science background to the investment team. Before joining Sofinnova in 2008, he was President of Research and Development at Elan, having earlier held R&D leadership at Schwarz Pharma AG and various senior scientific and clinical roles at Pharmacia (now Pfizer). He earned his MD and PhD from the University of Gothenburg, Sweden, and is a board-certified surgeon with a PhD in Experimental Biology.
- Where does Lars Ekman work?
- Lars Ekman is Executive Partner, Private Equity at Sofinnova Ventures and Board director at Aeovian Pharmaceuticals and Board director at Sophiris BIO.
- What does Lars Ekman invest in?
- Lars Ekman invests in Biotech.
- What check size does Lars Ekman write?
- Lars Ekman typically writes checks of $100K – $5M.
- What boards does Lars Ekman sit on?
- Lars Ekman holds tracked board seats at Aeovian, Aeovian Pharmaceuticals, Afyx Therapeutics, Amarin (AMRN), Prothena (PRTA), Sophiris (SPHS), Spark (ONCE).
- Where did Lars Ekman go to school?
- Lars Ekman studied at University of Gothenburg (MD, PhD, Medicine and Molecular Biology).
Same school
Also attended University of Gothenburg48
+ 42 more
